Clinical Trial Update: An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) [Phase 3]

View source ↗

Summary

An extension study to evaluate the long-term safety of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM); it is a Phase 3 trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloid Cardiomyopathy

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Status: ENROLLING_BY_INVITATION